Q1 FY2027 · Presentation
LISRAYA Approval · 27 pages
Read Roivant Sciences Ltd.'s results firsthand
Preview the first 2 pages of this presentation
Create a free account to start reading
Full documents are included with Professional
Roivant Sciences Ltd.
38.23
USD
+2.19
(+6.08%)
Roivant Sciences Ltd. Documents
Q1 FY2027 documents
Earnings release
8 pages
Aug 6, 2026
Quarterly report
74 pages
Aug 6, 2026
Presentation
Mosliciguat in PH-ILD PHocus Study Topline Results
30 pages
Presentation
LISRAYA Approval
27 pages
Presentation
Roivant Sciences Ltd - Q1 2027 - Slides
22 pages
Press release
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lun
2 pages
Sep 8, 2026
Press release
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. _ Roivant Sciences Ltd_
7 pages
Aug 28, 2026